NEW YORK, May 8, 2014 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's May cover story http://www.pharmexec.com/pharmexec/Top+Feature/2014-Brand-of-the-Year/ArticleStandard/Article/detail/842582 and the interactive eBook "iDigital Marketing Winning Brands," available for free in the iTunes Store (https://itunes.apple.com/us/app/pharma-sci/id568221918?mt=8), highlight in depth the publication's eighth annual Brand of The Year awards.
This year, in an innovative move, the Editors of Pharm Exec decided to choose two recipients in two categories, which reflects a trend in the industry in general.
The winners are Teva's Copaxone, a specialty drug for the treatment of chronic disease (in this case MS), and Corcept's KORLYM, an orphan drug for Cushing Disease, a rare condition --two most popular categories of biopharmaceutical R&D activity.
Both drugs have relied heavily on digital marketing to push their message out to physicians and the patient community. It is fitting therefore that marketing executives from the winning drug companies (Teva and Corcept) be recognized for their innovative approaches at CBI's iPharma 2014 summit on May 8-9 In New York.
CBI is Pharmaceutical Executive's conference organization. The stories are also highlighted in a new Pharm Exec digital, interactive eBook, "The iDigital Marketing For Winning Brands."
A monthly magazine and daily online publication, PHARMACEUTICAL EXECUTIVE offers policy analysis and in-depth business coverage of the global biopharmaceutical, vaccine and medical device industries.
EDITOR WILLIAM LOONEY ON PHARMACEUTICAL EXECUTIVE'S SELECTION OF The Brand Of The Year: "Pharm Exec's Brand of the Year award is itself a brand with staying power-- our first recipient was Merck's Gardasil papillomavirus vaccine, which eight years later is still going strong as one of the company's 10 top-selling products. This year's winner, Teva's Copaxone, also pins the needle on the long tail, at 17 years on the market with an equally durable safety profile against its nemesis, the elusive autoimmune disease multiple sclerosis. But lest we be accused of being safely predictable, this year Pharm Exec decided to focus, too, on clinical and marketing achievement for an orphan-status rare disease drug, calling out Bay Area start-up Corcept Therapeutics' initiative? in repurposing an old drug, mifepristone, for a new indication as the first treatment for Cushing's syndrome, a disabling metabolic disorder that is habitually under-diagnosed. Corcept's KORLYM carries larger potential as the test launch for a new class of medicines to address how the 'fight or flight' hormone, cortisol, works as a precursor to many chronic life-threatening conditions that affect millions of patients outside the rare disease space. It's literally a new way to think about disease."
CBI's iPharma 2014 -- the industry's leading marketing innovation summit -- is the most compelling life sciences meeting, uniting key stakeholders in the world of digital marketing, strategy, branding, innovation, sales, and IT to share the latest trends and real-world approaches to developing effective and innovative multi-channel campaigns.
For more information, contact: Marylyn Donahue, 212-951-6742
Read more news from Pharmaceutical Executive.
SOURCE Pharmaceutical Executive